Clinical-immunological Features of DNER Ataxia

• Conditions: DNER Ataxia
• Interventions: Genetic: Description of clinical characteristic and genetic tumors

• Registration Number: NCT05225896
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Using a retrospective cohort of 34 patients with DNER ataxia, we will characterize clinical presentation, tumor associations, and outcomes.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2021-06-15
• Primary Completion: 2021-12-15
• Study First Submitted: 2022-01-25
• Status Verified: 2022-02
• Study First Submitted QC: 2022-02-04
• Last Update Submitted: 2022-02-04
• Study First Posted: 2022-02-07
• Last Update Posted: 2022-02-07
• Study Completion: 2022-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

• Patient > 18 years old
• Patient with neurological disorder
• Patient with DNER antibodies in sera or CSF

Read More

Exclusion Criteria

• • No available clinical data
• Patient without DNER antibodies or neurological disorder

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
DNER ataxia	Description of clinical characteristic and genetic tumors	Patients with well-characterized DNER antibodies.

Primary Outcome Measures

Name	Time	Method
Modified Rankin scale (mRS)	6 month after the beginning of study	Residual neurological disability as assessed by the modified Rankin scale (mRS) score at last visit)

Trial Locations

Locations (1)

HCL Hôpital Neurologique / Groupement EST; 🇫🇷 Bron, France